Neoplasms

Blood and Lymph Conditions

All Conditions

Hematologic Neoplasms

Peripheral blood stem cells from Haploidentical donor

Peripheral blood stem cells from unrelated donor with a single allele or antigen mismatch at HLA-A, -B, -C, or -DRB1 and no concurrent DQB1 mismatch (9/10) shown by confirmatory typing

Hematopoietic stem cell transplantation with PBSC

Peripheral blood stem cells

Johannes Schetelig, Prof Dr med

The goal of this trial is to compare the outcome after partially matched (single mismatch) unrelated donor transplantation with haploidentical transplantation in a randomized controlled setting.

For patients with an indication for allogeneic HCT, the search for a stem cell donor is a challenge. 20% of patients who need an allograft have an HLA-identical sibling available, and for approximately 70% of the remaining patients, a suitable, HLA-well-matched (10/10), unrelated volunteer can be found. For the remaining patients, partially matched (single mismatch) unrelated donors or haploidentical donors are alternative options.

Recently published retrospective single center and registry studies suggest comparable outcomes for HCT from unrelated donors matched at HLA -A, -B, -C, and -DRB1 and haploidentical donors. The number of haploidentical HCT evaluated in these studies was still relatively small and a selection bias for the retrospective comparisons cannot be excluded.

The goal of this trial is to evaluate overall survival of patients with high-risk AML, ALL or MDS after partially matched unrelated or haploidentical donor transplantation..

Haploidentical Donor vs mMUD in Hematological Malignancies

A Randomized Controlled Trial Comparing Outcome After Hematopoietic Cell Transplantation From a Partially Matched Unrelated Versus Haploidentical Donor

Overall survival calculated from the time of randomization will be the primary endpoint of this trial. Death from any reason will be considered as event.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Haploidentical Donor vs mMUD in Hematological Malignancies	NCT03275636	AML ALL MDS	Peripheral bloo...	18 Years -	DKMS gemeinnützige GmbH
Haploidentical Donor vs mMUD in Hematological Malignancies	NCT03275636	AML ALL MDS	Peripheral bloo...	18 Years -	DKMS gemeinnützige GmbH

Spots Global Cancer Trial Database for donor comparison